




The relative strengths and weaknesses of Foghorn Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Foghorn Therapeutics Inc compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 8.1% points. The greatest weakness of Foghorn Therapeutics Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is 134%, being 79% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	240,181
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	58,436
Liabilities, Non-Current	304,670
Other Assets	45,735
Other Compr. Net Income	3,160
Other Expenses	4,226
Other Liabilities	0
Other Net Income	13,706
Other Revenues	34,155
Property and Equipment	0
Research and Development	109,689
Selling, General and Administrative Expense	32,372

Output Variable	Value in 1000 USD
Assets	285,916
Liabilities	363,106
Expenses	146,287
Revenues	34,155
Stockholders Equity	-77,190
Net Income	-98,426
Comprehensive Net Income	-96,846
BaseVar	423,165
ECR before Limited Liability	-82%
Economic Capital Ratio	134%